Rat models as tool to develop new immunotherapies

Immunological Reviews

Volumn 184, Issue , 2001, Pages 117-128

  Link, Hans ^a   Xiao, Bao Guo ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; B LYMPHOCYTE; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VITRO STUDY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; T LYMPHOCYTE;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOTHERAPY; MYASTHENIA GRAVIS; RATS;

EID: 0035706374     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065x.2001.1840111.x     Document Type: Review

References (58)

1. Myelin/axonal pathology in interleukin-12 induced serial relapses of experimental allergic ncephalomyelitis in the Lewis rat
2. Nitric oxide plays a critical role in the recovery of Lewis rats from experimental autoimmune encephalomyelitis and the maintenance of resistance to reinduction
3. Magnetic resonance imaging of PLP-induced experimental allergic encephalomyelitis in Lewis rats
4. On the role of peripheral macrophages during active experimental allergic encephalomyelitis (EAE)
5. Pertussis toxin-induced hyperacute autoimmune encephalomyelitis in Lewis rats is correlated with increased expression of inducible nitric oxide synthase and tumor necrosis factor α
6. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology
7. Congenic mapping confirms a locus on rat chromosome 10 conferring strong protection against myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis
8. Disease progression in chronic relapsing experimental allergic encephalomyelitis is associated with reduced inflammation-driven production of corticosterone
9. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions
10. Ganglioside changes in brain in chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat
11. Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-β mRNA
12. Curative effects of recombinant human Interleukin-6 in DA rats with protracted relapsing experimental allergic encephalomyelitis
13. Suppression of experimental autoimmune encephalomyelitís by intravenously administered polyclonal immunoglobulins
14. Interferon-β treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T-cell infiltration
15. Acute neuronal apoptosis in a rat model of multiple sclerosis
16. Characterization of acute versus chronic relapsing autoimmune encephalomyelitis in DA rats
17. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor
18. Treatment of passively transferred experimental autoimmune myasthenia gravis using papain
19. Autoimmune response to acetylcholine receptors in myasthenia gravis and its animal model
20. Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs
21. Oral tolerance in EAE: Reversal of tolerance by T helper cell cytokines
22. Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein
23. Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 peptide
24. Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis. A preliminary report of intranasal induction of tolerance with retinal antigens
25. Intranasal administration of retinal antigens suppresses retinal antigen-induced experimental autoimmune uveoretinitis
26. + T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production
27. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23)
28. Antigen-specific immunotherapy of autoimmune disease: A commentary
29. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity
30. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor
31. Antigen-driven peripheral immune tolerance: Suppression of experimental autoimmmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen
32. Aerosol insulin induces regulatory CD8 γδ T cells that prevent murine insulin-dependent diabetes
33. Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-gamma-expressing Th1-like cells and up-regulation of TGF-β mRNA in mononuclear cells
34. Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: Synergistic effects of MBP 68-86 and 87-99
35. Cytokine-induced autoimmune disorders
36. Oral cytokine administration
37. IL-4 is a differentiation factor for transforming growth factor-β secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis
38. Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats
39. TGF-β1 inhibits protracted-relapsing experimental autoimmune encephalomyelitis by activating dendritic cells
40. Dendritic cell-derived nitric oxide is involved in IL-4-induced suppression of experimental allergic encephalomyelitis (EAE) in Lewis rats
41. The complexity of cytokine treatment in ongoing EAE reduced with MBP peptide 68-86 in Lewis rats
42. Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes
43. Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis
44. Dendritic cells and the control of immunity
45. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer
46. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
47. Autoantigen-pulsed dendritic cells induce tolerance to experimental allergic encephalomyelitis (EAE) in Lewis rats
48. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor
49. Induction of interferon-γ, interleukin-4, and transforming growth factor-β in rats orally tolerized against experimental autoimmune myasthenia gravis
50. B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis
51. Synthetic peptides fail to induce nasal tolerance to experimental autoimmune myasthenia gravis
52. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment
53. Mechanism of nasal tolerance reduced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis
54. Nasal tolerance in experimental autoimmune myasthenia gravis: Induction of protective tolerance in primed animals
55. T-cell activation and receptor downmodulation precede deletion induced by mucosally administered antigen
56. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering
57. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen
58. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response